Last edition
News about "FOLFIRI "
Pfizer Reports Improved Response Rates with BRAFTOVI Regimen in Metastatic Colorectal Cancer
New data from the BREAKWATER study show that Pfizer’s BRAFTOVI-based regimen significantly improved response rates in patients with BRAF V600E–mutant metastatic colorectal cancer, supporting the potential use of flexible chemotherapy backbones.
FOLFIRI | 12/01/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members